Cohen David E 4
4 · Evommune, Inc. · Filed Jun 3, 2026
Research Summary
AI-generated summary of this filing
Evommune (EVMN) Director David E. Cohen Sells Shares, Receives Award
What Happened
David E. Cohen, a director of Evommune, sold two blocks of common stock on 2026-06-02 and received a derivative award the same day. He disposed of 5,456 shares at a weighted-average price of $20.21 for $110,266 and 600 shares at a weighted-average price of $21.38 for $12,828 (aggregate proceeds ~$123,094). He was also granted a 15,673-share derivative award (reported at $0.00), described in the filing as subject to vesting conditions.
Key Details
- Transaction date: 2026-06-02; Form 4 filed 2026-06-03 (timely filing).
- Sales: 5,456 shares at $20.21 (weighted avg; prices ranged $20.00–$20.99 per footnote) = $110,266; 600 shares at $21.38 (weighted avg; prices ranged $21.06–$21.75 per footnote) = $12,828.
- Award: 15,673-share derivative award reported at $0.00 (no cash paid). Footnote F4: award vests at the earlier of the first anniversary of the grant date or the issuer’s next annual meeting, subject to continuous service.
- Footnote F1: the sales were made pursuant to a Rule 10b5-1 trading plan adopted March 3, 2026 (pre-arranged plan).
- Shares owned after the transactions: not specified in the provided excerpt — see the full Form 4 for post-transaction holdings.
Context
Sales executed under a Rule 10b5-1 plan are pre-planned and are commonly viewed as routine liquidity events rather than fresh statements of insider sentiment. The derivative award appears to be an equity grant (vesting conditions apply); the filing does not indicate a cashless exercise or immediate sale of award shares. For full details (exact post-transaction holdings and any additional clauses), consult the complete Form 4 (Accession: 0001347383-26-000003).
Insider Transaction Report
- Sale
Common Stock
[F1][F2]2026-06-02$20.21/sh−5,456$110,266→ 18,209 total - Sale
Common Stock
[F1][F3]2026-06-02$21.38/sh−600$12,828→ 17,609 total - Award
Stock Option (Right to buy)
[F4]2026-06-02+15,673→ 15,673 totalExercise: $19.82Exp: 2036-06-01→ Common Stock (15,673 underlying)
Footnotes (4)
- [F1]The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2026.
- [F2]The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $20.00 to $20.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.06 to $21.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
- [F4]The shares subject to the option award shall vest at the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.